As the S&P 500 built on the strong performance in 2025 with a modest gain in January, are there any compelling investment ideas out there that may have flown under your radar?
Below is a list of January Buy recommendations made by analysts who had no other bullish recommendations over the past 3 months.
For your directory assistance, we’ve classified the opportunities by sector.
Healthcare
AVITA Medical (RCEL) – Longtime analyst Wall Street Titan says it has an innovative automated wound-healing regenerative system that works faster than the standard of care and provides superior results, and the resolution of the CMS payment issue is a catalyst. – Avita Medical: Set Up For A Turnaround
Moderna (MRNA) – BioCGT Investor, who focuses on healthcare stocks, says this is a speculative ‘buy’ rating for high-risk, long-term investors, supported by disciplined cost reductions and a maturing pipeline with multiple oncology catalysts. – Moderna: V940/Keytruda Data And Vaccine Revenues Drive A High-Risk Recovery Story (Editor’s note: Shares have rallied since the article was published.)
Financials
Medallion Financial (MFIN) – Longtime analyst Adam Schadt says it has consistently grown its asset base and maintained a rising net interest margin while it reinstated and increased its dividend, and boasts strong insider ownership. – Medallion Financial Is Consistently Delivering Strong Returns
Yuanbao (YB) – Friso Alenus, a junior financial analyst at a private equity and venture capital firm, says it is growing revenue at ~30% year-over-year with 13 consecutive quarters of profitability, yet trades at a P/E of only 5x, while the strong balance sheet provides a margin of safety. – Yuanbao: High-Growth AI Insurtech Trading Like A Value Stock, Top Pick 2026
Lincoln National (LNC) – Independent trader Growth Stock Hunter says it trades at a deep discount, with a 4.2x P/E and 40% below
Read the full article here